ישראל - עברית - Ministry of Health

sanofi israel ltd - glimepiride - טבליה - glimepiride 3 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

ישראל - עברית - Ministry of Health

sanofi israel ltd - glimepiride - טבליה - glimepiride 4 mg - glimepiride - glimepiride - non-insulin-dependent diabetes melitus ( adult-onset diabetes, type ii diabetes), when diet, regular physical exercise, and weight reduction alone cannot maintain therapeutically suitable blood glucose levels.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - saxagliptin as hydrochloride - טבליות מצופות פילם - saxagliptin as hydrochloride 2.5 mg - saxagliptin - saxagliptin - monotherapy: onglyza is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus.onglyza should not be used in patients with esrdcombination therapy: add-on combination: onglyza is indicated in patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, a thiazolidinedione (tzd), or a sulfonylurea (su), when the single agent alone, with diet and exercise, does not provide adequate glycemic control.initial combination: onglyza is indicated for use as initial combination therapy with metformin, as an adjunct to diet and exercise, to improve glycemic control in patients with type 2 diabetes mellitus when dual saxagliptin and metformin therapy is appropriate.onglyza should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis. in combination with insulin (with or without metformin), when this regimen alone, with diet and exercise, does not provide adequate glycaemic control.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - repaglinide - טבליה - repaglinide 0.5 mg - repaglinide - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - repaglinide - טבליה - repaglinide 1 mg - repaglinide - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

teva pharmaceutical industries ltd, israel - repaglinide - טבליה - repaglinide 2 mg - repaglinide - repaglinide - treatment of type ii diabetes.

ישראל - עברית - Ministry of Health

perrigo israel agencies ltd, israel - calcium carbonate - טבליות לעיסות - calcium carbonate 500 mg - calcium carbonate - calcium carbonate - antacid, calcium supplement.

ישראל - עברית - Ministry of Health

perrigo israel agencies ltd, israel - calcium carbonate - טבליות לעיסות - calcium carbonate 500 mg - calcium carbonate - calcium carbonate - antacid, calcium supplement.

ישראל - עברית - Ministry of Health

teva israel ltd - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or